Global Cancer Monoclonal Antibodies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Cancer Monoclonal Antibodies Market is presumed to reach the market size of nearly USD 435.43 Billion by 2032 from USD 92.94 Billion in 2023 with a CAGR of 18.72% under the study period 2024-2032.

Cancer monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to bind specifically to cancer cells or proteins involved in cancer growth. Derived from a single clone of cells, these antibodies target unique antigens present on or within cancer cells, offering precise therapeutic options for cancer treatment. They mark cancer cells for destruction by the immune system, block growth signals, or deliver cytotoxic agents directly to the tumor site. Monoclonal antibodies are integral to targeted cancer therapies, addressing various cancers, including breast, lymphoma, and leukemia. Their specificity and targeted approach help minimize damage to healthy cells, making them a pivotal advancement in oncology.

MARKET DYNAMICS

The cancer monoclonal antibodies market is expanding rapidly, fueled by the propelling prevalence of cancer worldwide. Monoclonal antibodies offer targeted therapy that is increasingly preferred due to its precision and reduced side effects compared to traditional treatments. This precision medicine approach aligns with the growing trend towards personalized healthcare, further boosting market growth. Advancements in biotechnology and an improved understanding of cancer biology are creating new opportunities for developing innovative monoclonal antibodies. Researchers continuously discover novel targets and pathways, creating next-generation mAbs with enhanced efficacy and safety profiles. The development of combination therapies, where monoclonal antibodies are used alongside other treatments such as chemotherapy or immunotherapy, also expands their therapeutic potential and cancer monoclonal antibodies market reach.

The increasing investment in cancer research and development by the public and private sectors is another key factor driving the cancer monoclonal antibodies market. Pharmaceutical companies are actively pursuing new mAbs and clinical trials, leading to a steady pipeline of potential therapies. Additionally, the growing emphasis on early cancer detection and prevention is expected to contribute to the increased adoption of monoclonal antibody-based diagnostics. However, high development and production costs may hinder market growth. The substantial investment required to research, develop, and manufacture monoclonal antibodies can limit accessibility and affect overall market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cancer Monoclonal Antibodies. The growth and trends of Cancer Monoclonal Antibodies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cancer Monoclonal Antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Humanized
Human
Chimeric
Murine

By Application

Blood Cancer
Breast Cancer
Lung Cancer
Melanoma
Colorectal Cancer
Liver Cancer
Others

By End-user

Hospitals
Research Institutes
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Monoclonal Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Monoclonal Antibodies market include F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Co., Merck & Co., GlaxoSmithKline Plc, Johnson & Johnson, Amgen Inc., Novartis AG, AstraZeneca Plc, Eli Lilly And Company, AbbVie. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11216177

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CANCER MONOCLONAL ANTIBODIES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Humanized Historic and Forecast Sales By Regions
5.4. Human Historic and Forecast Sales By Regions
5.5. Chimeric Historic and Forecast Sales By Regions
5.6. Murine Historic and Forecast Sales By Regions

6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Blood Cancer Historic and Forecast Sales By Regions
6.4. Breast Cancer Historic and Forecast Sales By Regions
6.5. Lung Cancer Historic and Forecast Sales By Regions
6.6. Melanoma Historic and Forecast Sales By Regions
6.7. Colorectal Cancer Historic and Forecast Sales By Regions
6.8. Liver Cancer Historic and Forecast Sales By Regions
6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data Analysis By End-user
7.3. Hospitals Historic and Forecast Sales By Regions
7.4. Research Institutes Historic and Forecast Sales By Regions
7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER MONOCLONAL ANTIBODIES COMPANIES

9.1. Cancer Monoclonal Antibodies Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF CANCER MONOCLONAL ANTIBODIES INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. F. Hoffmann-La Roche Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Bristol Myers Squibb Co.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Merck & Co.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. GlaxoSmithKline Plc
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Johnson & Johnson
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Amgen Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Novartis AG
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. AstraZeneca Plc
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Eli Lilly And Company
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. AbbVie
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies